A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zaawansowany nowotwór lite z mutacją KRAS G12D
- •Progresja choroby mimo wcześniejszego leczenia standardowego lub brak tolerancji na standardowe leczenie
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (ECOG 0-1)
✗ Disqualifies
- •Wcześniejsze leczenie inhibitorami KRAS G12D
- •Występowanie innego nowotworu w ciągu ostatniego roku
- •Historia przeszczepu narządów lub komórek macierzystych
- •Niekontrolowane, poważne problemy zdrowotne
- •Nieprawidłowości w zapisie elektrokardiograficznym
- •Niewystarczająca funkcja narządów wewnętrznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (34)
Mayo Clinic Hospital
Phoenix, United States
Stanford University
Palo Alto, United States
UCLA Healthcare Hematology-Oncology
Santa Monica, United States
Sarah Cannon Research Institue At Healthone
Denver, United States
Florida Cancer Specialists
Sarasota, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, United States
Dana Farber Cancer Institute
Boston, United States
Hackensack University Medical Center
Hackensack, United States
Weill Cornell Medicine
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Jefferson University Hospitals
Philadelphia, United States
Scri Oncology Partners
Nashville, United States
Md Anderson Cancer Center
Houston, United States
Chris Obrien Lifehouse
Camperdown, Australia
St Vincent'S Hospital Sydney
Darlinghurst, Australia
Peter Maccallum Cancer Centre
Melbourne, Australia
The Alfred Hospital
Melbourne, Australia
Linear Clinical Research
Nedlands, Australia
Cliniques Universitaires Ucl Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen (Uza)
Edegem, Belgium
Universitair Ziekenhuis (Uz) Leuven
Leuven, Belgium
The Ottawa Hospital Cancer Center
Ottawa, Canada
Princess Margaret Cancer Center
Toronto, Canada
Centre Leon Berard
Lyon, France
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
Irccs Istituto Clinico Humanitas
Rozzano, Italy
Centro Ricerche Cliniche Di Verona
Verona, Italy
National Cancer Center Hospital East
Chiba, Japan
The Cancer Institute Hospital of Jfcr
Tokyo, Japan
Hospital General Universitario Vall D Hebron
Barcelona, Spain
Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario Quironsalud Madrid
Madrid, Spain
Trial contact
Incyte Corporation Call Center (US)
Incyte Corporation Call Center (ex-US)
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.